News & Events
3rd Annual Ophthalmology Innovation Summit
Orlando, Florida
October 20, 2011
American Academy of Ophthalmology
Orlando, Florida
October 21-25, 2011
BEAVRS Meeting
Canterbury, England
November 10-11, 2011
ISOPT
Vienna, Austria
December 1-2, 2011
Asia Pacific Vitreo-Retina Society Congress
Hyderabad, India
December 1-3, 2011
Retina 2012
Wailea, Maui
January 15-20, 2012
Angiogenesis 2012
Coral Gables, Florida
February 4, 2012
Understanding AMD
Learn about the causes of wet AMD and why it's important to understand current treatment options.
NeoVista leadership
An experienced management team, dedicated venture partners — and a growing list of NeoVista accomplishments.
Innovations
NeoVista's proprietary technology makes epimacular brachytherapy a potential addition to wet AMD treatment options.
CABERNET
This important clinical study is now under way; learn more about its design and key endpoints.
About Wet AMD
NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.
The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.
Learn more about wet AMD.
Learn more about NeoVista, Inc.
Learn more about epimacular beta radiation therapy, our innovative core technology.
Learn more about current clinical trials of NeoVista technology.
In the News
Sky News - Radiation Beams Used To Restore Eyesight
Saturday November 21, 2009
Thomas Moore, health correspondent
German Television - Makula-Degeneration: Neue Behandlung rettet Augenlicht
Videos & Animations
- Visit our new Multimedia page, with video presentations and animated procedures available for viewing.